Diagnóstico y tratamiento médico de la epilepsia

Pedro Luis Rodríguez García

Texto completo:

PDF (665 KB)

Resumen

OBJETIVO: Proponer unas guías prácticas basadas en la mejor evidencia científica y clínica disponible para el manejo diagnóstico y el tratamiento médico del paciente con epilepsia.

DESARROLLO: En una primera parte se hace un análisis de las definiciones de crisis epiléptica y de epilepsia formuladas por la Liga Internacional Contra la Epilepsia (ILAE). Varios elementos de la definición de epilepsia más reciente resultan polémicos y otros constituyen un paso de avance con respecto a las concepciones originales. Se revisan los criterios con respecto a: 1) La epilepsia considerada como enfermedad, 2) La distinción de las crisis epilépticas “no provocadas” y reflejas, 3) La valoración del riesgo de recurrencia de las crisis epilépticas, y 4) Las implicaciones prácticas del término epilepsia “resuelta”. En la segunda parte se aborda el manejo médico especializado de los pacientes con epilepsia, específicamente la organización de la consulta especializada, las ocho medidas de calidad o estándares para el manejo señaladas por la Academia Americana de Neurología, y las recomendaciones sobre el régimen de vida e integración social y los principios de la terapéutica con los fármacos antiepilépticos orales. En este último acápite se incluyen las recomendaciones para la selección del fármaco antiepiléptico oral según el tipo de crisis epiléptica y las características del paciente. Al final se valoran determinadas características farmacológicas de los fármacos antiepilépticos disponibles y otros que han sido incorporados en los últimos años.

CONCLUSIONES: El diagnóstico y tratamiento médico de la epilepsia en la práctica clínica debe de considerar las recientes publicaciones sobre el tema y las diferentes perspectivas aportadas por los expertos. Al final, el manejo óptimo de esta enfermedad debe de lograrse a través de la discusión formal de las opciones disponibles entre el médico de asistencia y el paciente o sus cuidadores.

Palabras clave

Fármacos anticonvulsivantes; Convulsiones; Epilepsia; Guía de práctica clínica; Neurología

Referencias

Fisher RS, van Emde Boas W, Blume W, Elger C, Genton P, Lee P, et al. Epileptic seizures and epilepsy: definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). Epilepsia. 2005;46:470–472.

Berg AT, Scheffer IE. New concepts in classification of the epilepsies: Entering the 21st century. Epilepsia. 2011;52(6):1058–62. doi: 10.1111/j.1528–1167.2011.03101.x

Fisher R, Acevedo C, Arzimanoglou A, Bogacz A, Cross H, Elger C, et al. A practical clinical definition of epilepsy. Epilepsia. 2014;55(4):475–82. doi: 10.1111/epi.12550.

Fountain NB, Van Ness PC, Swain–Eng R, Bever CT. Quality improvement in neurology: AAN epilepsy quality measures. Report of the Quality Measurement and Reporting Committee of the American Academy of Neurology. Neurology. 2011;76:94–9.

García García RJ. Sexualidad, fertilidad y anticoncepción en adolescentes epilépticos: estado del arte y propuestas de conducta. Rev Cubana Neurol Neurocir. [Internet] 2011 [citado 3.3.2015];1(1):52–8. Disponible en: http://www.revneuro.sld.cu

García García RJ. Situaciones especiales en adolescentes epilépticos: embarazo, parto y lactancia. Rev Cubana Neurol Neurocir. [Internet] 2012 [citado 3.3.2015];2(1):47–55. Disponible en: http://www.revneuro.sld.cu

Rodríguez García PL. Diagnóstico y tratamiento del estado epiléptico. Rev Cubana Neurol Neurocir. [Internet] 2012 [citado 3.3.2015];2(2):150–66. Disponible en: http://www.revneuro.sld.cu

Andrade Machado R, Goicoechea Astencio A, Rodríguez García PL, Fernández Abreu Z, Santos Santos A, Garnier Ávila T, et al. Guías de prácticas clínicas para la atención y el manejo de los problemas médicos de las mujeres con epilepsia. Rev Cubana Neurol Neurocir. [Internet] 2013 [citado 3.3.2015];3(2):172–95. Disponible en: http://www.revneuro.sld.cu

Malkan A, Beran RG. An appraisal of the new operational definition of epilepsy––then and now. Epilepsy Behav. 2014 Dec;41:217–20. doi: 10.1016/j.yebeh.2014.09.084.

Mastrangelo M. Definition of Epilepsy: Comments. 9 September, 2013 [citado 3.3.2015]. Disponible en: http://www.ilae.org/Visitors/Centre/Definition–older.cfm

Abou–Khalil B, Gallagher M, Macdonald R. Epilepsies. En: Bradley's Neurology in Clinical Practice. Daroff RB, Fenichel GM, Jankovic J, Mazziotta JC. Saunders, an imprint of Elsevier Inc.; 2012. p. 1583–1633.

Reynolds E, Rodin E. The clinical concept of epilepsy. Epilepsia, 2009;50(Suppl. 3):2–7. doi: 10.1111/j.1528–1167.2009.02034.x

Seino M. Classification criteria of epileptic seizures and syndromes. Epilepsy Res. 2006 Aug;70 Suppl 1:S27–33.

Tuxhorn I, Kotagal P. Classification. Semin Neurol. 2008 Jul;28(3):277–88. doi: 10.1055/s–2008–1079332.

Beghi E, Carpio A, Forsgren L, Hesdorffer D, Malmgren K, Sander J, et al. Recommendation for a definition of acute symptomatic seizure. Epilepsia. 2010;51(4):671–5.

Kim LG, Johnson TL, Marson AG, Chadwick DW; MRC MESS Study group. Prediction of risk of seizure recurrence after a single seizure and early epilepsy: further results from the MESS trial. Lancet Neurol 2006;5:317–322.

Bonnett LJ, Tudur–Smith C, Williamson PR, Marson AG. Risk of recurrence after a first seizure and implications for driving: further analysis of the Multicentre study of early Epilepsy and Single Seizures. BMJ. 2010 Dec 7;341:c6477. doi: 10.1136/bmj.c6477.

Krauss G. Epilepsy is not resolved. Epilepsy Curr. 2014 Nov–Dec;14(6):339–40. doi: 10.5698/1535–7597–14.6.339.

Bradley PM, Lindsay B. Care delivery and self–management strategies for adults with epilepsy. Cochrane Database Syst Rev. 2008 Jan 23;(1):CD006244. doi: 10.1002/14651858.CD006244.pub2.

García–Martín G, Martín–Reyes G, Dawid–Milner MS, Chamorro–Muñoz MI, Pérez–Errazquin F, Romero–Acebal M. Gestión sanitaria de una consulta de epilepsia: factores implicados en la demanda asistencial y situación clínica de los pacientes. Rev Neurol. 2013 May 16;56(10):497–504.

Sociedad Española de Neurología. Plan estratégico nacional para el tratamiento integral de las enfermedades neurológicas. Madrid: Ibáñez&Plaza Asociados S.L.; 2002 [citado 3.3.2015]. Disponible en: http://www.sen.es/pdf/planacional.pdf

Rodríguez García PL, García García RJ, Betancourt Nápoles R, Bender del Busto JE, Aguilera Pacheco OR, Ortega Santiesteban O, et al. Propuesta de programa de la residencia de neurología en Cuba. Rev Cubana Neurol Neurocir. [Internet] 2015 [citado 3.3.2015];5(1):56–98. Disponible en: http://www.revneuro.sld.cu

Noachtar S, Winkler PA, Lüders HO. Surgical therapy of epilepsy. En: Brandt T et al., editors. Neurological disorders: course and treatment. San Diego: Academic Press; 2003. p. 235–44.

Noachtar S, Borggraefe I. Epilepsy surgery: A critical review. Epilepsy Behav. 2009 May;15(1):66–72. doi: 10.1016/j.yebeh.2009.02.028.

Hamer HM, Kostev K. Sociodemographic disparities in administration of antiepileptic drugs to adults with epilepsy in Germany: a retrospective, database study of drug prescriptions. CNS Drugs. 2014 Aug;28(8):753–9. doi: 10.1007/s40263–014–0187–x.

Szaflarski M. Social determinants of health in epilepsy. Epilepsy Behav. 2014 Dec;41:283–9. doi: 10.1016/j.yebeh.2014.06.013.

Schiltz NK, Koroukian SM, Singer ME, Love TE, Kaiboriboon K. Disparities in access to specialized epilepsy care. Epilepsy Res. 2013 Nov;107(1–2):172–80. doi: 10.1016/j.eplepsyres.2013.08.003.

Cisneros–Franco JM, Díaz–Torres MA, Rodríguez–Castañeda JB, Martínez–Silva A, Gutierrez–Herrera MA, San–Juan D. Impact of the implementation of the AAN epilepsy quality measures on the medical records in a university hospital. BMC Neurol. 2013 Aug 28;13:112. doi: 10.1186/1471–2377–13–112.

Rodríguez García PL, Rodríguez Pupo LR. Semiología Neurológica. Ecimed; 2012. p. .173–94.

Berg AT, Berkovic SF, Brodie MJ, Buchhalter J, Cross JH, Van Emde Boas W, et al. Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology. Epilepsia. 2010;51:676–85.

Nunes VD, Sawyer L, Neilson J, Sarri G, Cross JH. Diagnosis and management of the epilepsies in adults and children: summary of updated NICE guidance. BMJ. 2012 Jan 26;344:e281. doi: 10.1136/bmj.e281.

Siniscalchi A, Scaglione F, Sanzaro E, Iemolo F, Albertini G, Quirino G, et al. Effects of phenobarbital and levetiracetam on PR and QTc intervals in patients with post–stroke seizure. Clin Drug Investig. 2014 Dec;34(12):879–86. doi: 10.1007/s40261–014–0243–9.

Labate A, Ambrosio R, Gambardella A, Sturniolo M, Pucci F, Quattrone A. Usefulness of a morning routine EEG recording in patients with juvenile myoclonic epilepsy. Epilepsy Res. 2007 Oct;77(1):17–21.

Kwan P, Arzimanoglou A, Berg AT, Brodie MJ, Hauser W, Mathern G, et al. Definition of drug resistant epilepsy: Consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia. 2010;51(6):1069–77. doi: 10.1111/j.1528–1167.2009.02397.x

Ventola CL. Epilepsy management: newer agents, unmet needs, and future treatment strategies. P T. 2014 Nov;39(11):776–92.

Hao X, Goldberg D, Kelly K, Stephen L, Kwan P, Brodie MJ. Uncontrolled epilepsy is not necessarily the same as drug–resistant epilepsy: Differences between populations with newly diagnosed epilepsy and chronic epilepsy. Epilepsy Behav. 2013;29:4–6. http://dx.doi.org/10.1016/j.yebeh.2013.06.019

Foldvary–Schaefer N, Wyllie E. Epilepsy. Goetz's Textbook of Clinical Neurology. 3 ed. Philadelphia: Saunders Elsevier; 2007. p. 1213–44.

Conway J, Leppik I, Birnbaum A. Antiepileptic drug therapy in children. En: Swaiman KF, eds. Swaiman’s pediatric neurology. 5 ed. Saunders, 2012.

Vidal Vademecum Spain. Vademecum.es [citado 3.3.2015]. Disponible en: http://www.vademecum.es

Dobrin S. Seizures and epilepsy in adolescents and adults. Conn’s current therapy 2014. Bope E, eds. Elsevier Health Sciences. p. 658–66.

Paul SP, Rogers E, Wilkinson R, Paul B. Management of febrile convulsion in children. Emerg Nurse. 2015 May;23(2):18–25. doi: 10.7748/en.23.2.18.e1431.

Shih JJ, Ochoa JG. A systematic review of antiepileptic drug initiation and withdrawal. Neurologist. 2009 May;15(3):122–31. doi: 10.1097/NRL.0b013e3181901ad3.

Krumholz A, Wiebe S, Gronseth GS, Gloss DS, Sanchez AM, Kabir AA, et al. Evidence–based guideline: Management of an unprovoked first seizure in adults. Neurology. 2015;84(16):1705–13. doi: 10.1212/WNL.0000000000001487.

Zaccara G, Perucca E. Interactions between antiepileptic drugs, and between antiepileptic drugs and other drugs. Epileptic Disord. 2014 Dec;16(4):409–31. doi: 10.1684/epd.2014.0714.

Modi AC, Monahan S, Daniels D, Glauser TA. Development and validation of the Pediatric Epilepsy Medication Self–Management Questionnaire. Epilepsy Behav. 2010 May;18(1–2):94–9. doi: 10.1016/j.yebeh.2010.03.009.

Modi AC, Guilfoyle SM, Morita DA, Glauser TA. Development and reliability of a correction factor for parent–reported adherence to pediatric antiepileptic drug therapy. Epilepsia. 2011 Feb;52(2):370–6. doi: 10.1111/j.1528–1167.2010.02789.x.

Brodie MJ, Sills GJ. Combining antiepileptic drugs––rational polytherapy? Seizure. 2011 Jun;20(5):369–75. doi: 10.1016/j.seizure.2011.01.004.

Brodie MJ, Covanis A, Gil–Nagel A, Lerche H, Perucca E, Sills GJ, et al. Antiepileptic drug therapy: does mechanism of action matter? Epilepsy Behav. 2011 Aug;21(4):331–41. doi: 10.1016/j.yebeh.2011.05.025.

Schmidt D, Schachter SC. Drug treatment of epilepsy in adults. BMJ. 2014 Feb 28;348:g254. doi: 10.1136/bmj.g254.

Samuels M, Ropper A. Adams y Víctor, Principios de Neurología. 9 ed. McGraw–Hill Education; 2011.

Cuba/Ministerio de Salud Pública. Formulario nacional de medicamentos. 4 ed. Editorial Ciencias Médicas; 2014.

Star K, Edwards IR, Choonara I. Valproic acid and fatalities in children: a review of individual case safety reports in VigiBase. PLoS One. 2014 Oct 10;9(10):e108970. doi: 10.1371/journal.pone.0108970.

National Center for Biotechnology Information. PubChem Compound Database; CID=3121, [citado 3.3.2015]. Disponible en: http://pubchem.ncbi.nlm.nih.gov/compound/3121

Miranda Herrero MC, Alcaraz Romero AJ, Escudero Vilaplana V, Fernández Lafever SN, Fernández–Llamazares CM, Barredo Valderrama E, et al. Pharmacological interaction between valproic acid and carbapenem: ¿What about levels in pediatrics? Eur J Paediatr Neurol. 2014 Dec 20. pii: S1090–3798(14)00211–6. doi: 10.1016/j.ejpn.2014.12.010.

Montouris G, Abou–Khalil B. The first line of therapy in a girl with juvenile myoclonic epilepsy: should it be valproate or a new agent? Epilepsia. 2009 Sep;50 Suppl 8:16–20. doi: 10.1111/j.1528–1167.2009.02230.x.

National Center for Biotechnology Information. PubChem Compound Database; CID=2554 [citado 3.3.2015]. Disponible en: http://pubchem.ncbi.nlm.nih.gov/compound/2554

Powell G, Saunders M, Rigby A, Marson AG. Immediate–release versus controlled–release carbamazepine in the treatment of epilepsy. Cochrane Database Syst Rev. 2014 Dec 3;12:CD007124. doi: 10.1002/14651858.CD007124.pub4.

E L omairi N, Abourazzak S, Chaouki S, Atmani S, Hida M. Drug Reaction with Eosinophilia and Systemic Symptom (DRESS) induced by carbamazepine: a case report and literature review. Pan Afr Med J. 2014 May 2;18:9. doi: 10.11604/pamj.2014.18.9.3799.

Caudle KE, Rettie AE, Whirl–Carrillo M, Smith LH, Mintzer S, Lee MT, Klein TE, Callaghan JT. Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and HLA–B genotypes and phenytoin dosing. Clin Pharmacol Ther. 2014 Nov;96(5):542–8. doi: 10.1038/clpt.2014.159.

National Center for Biotechnology Information. PubChem Compound Database; CID=1775 [citado 3.3.2015]. Disponible en: http://pubchem.ncbi.nlm.nih.gov/compound/1775

Topcu H, Gokcinar D, Akcaboy ZN, Karabeyoglu I, Unal T. Phenytoin induced toxic epidermal necrolysis. J Coll Physicians Surg Pak. 2014 Nov;24(11 Suppl 3):S267–9. doi: 11.2014/JCPSP.S267S269.

Oelze LL, Pillow MT. Phenytoin–induced drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: a case report from the emergency department. J Emerg Med. 2013 Jan;44(1):75–8. doi: 10.1016/j.jemermed.2011.05.052.

Chung WH, Chang WC, Lee YS, Wu YY, Yang CH, Ho HC, et al. Genetic variants associated with phenytoin–related severe cutaneous adverse reactions. JAMA. 2014 Aug 6;312(5):525–34. doi: 10.1001/jama.2014.7859.

Chaabane A, Ben Fadhel N, Chadli Z, Ben Fredj N, Boughattas NA, Aouam K. Phenobarbital–Induced DRESS: A Lichenoïd Picture. Iran J Allergy Asthma Immunol. 2014 Dec;13(6):453–5.

Glauser TA, Cnaan A, Shinnar S, Hirtz DG, Dlugos D, Masur D, et al. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy. N Engl J Med. 2010 Mar 4;362(9):790–9. doi: 10.1056/NEJMoa0902014.

Glauser TA, Cnaan A, Shinnar S, Hirtz DG, Dlugos D, Masur D, et al. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy: initial monotherapy outcomes at 12 months. Epilepsia. 2013 Jan;54(1):141–55. doi: 10.1111/epi.12028.

Bentué–Ferrer D, Tribut O, Verdier MC. Suivi thérapeutique pharmacologique de l’éthosuximide [Therapeutic drug monitoring of ethosuximide]. Therapie. 2012 Jul–Aug;67(4):391–6. doi: 10.2515/therapie/2012035. [Article in French]

Anyanwu C, Ghavami F, Schuelein M, Motamedi GK. Ethosuximide–induced conversion of typical childhood absence to Rolandic spikes. J Child Neurol. 2013 Jan;28(1):111–4. doi: 10.1177/0883073812439250.

Yang LP, Scott LJ. Clobazam: in patients with Lennox–Gastaut syndrome. CNS Drugs. 2012 Nov;26(11):983–91. doi: 10.1007/s40263–012–0007–0.

Conry JA, Ng YT, Kernitsky L, Mitchell WG, Veidemanis R, Drummond R, et al. Stable dosages of clobazam for Lennox–Gastaut syndrome are associated with sustained drop–seizure and total–seizure improvements over 3 years. Epilepsia. 2014 Apr;55(4):558–67. doi: 10.1111/epi.12561.

National Center for Biotechnology Information. PubChem Compound Database; CID=2802 [citado 3.3.2015]. Disponible en: http://pubchem.ncbi.nlm.nih.gov/compound/2802

Sankar R, Chung S, Perry MS, Kuzniecky R, Sinha S. Clinical considerations in transitioning patients with epilepsy from clonazepam to clobazam: a case series. J Med Case Rep. 2014 Dec 16;8:429. doi: 10.1186/1752–1947–8–429.

Dalic L, Mullen SA, Roulet Perez E, Scheffer I. Lamotrigine can be beneficial in patients with Dravet syndrome. Dev Med Child Neurol. 2015 Feb;57(2):200–2. doi: 10.1111/dmcn.12593.

Won HK, Lee JW, Song WJ, Klaewsongkram J, Kang MG, Park HK, et al. Lamotrigine–induced toxic epidermal necrolysis confirmed by in vitro granulysin and cytokine assays. Asia Pac Allergy. 2014 Oct;4(4):253–6. doi: 10.5415/apallergy.2014.4.4.253.

Pulman J, Jette N, Dykeman J, Hemming K, Hutton JL, Marson AG. Topiramate add–on for drug–resistant partial epilepsy. Cochrane Database Syst Rev. 2014 Feb 25;2:CD001417. doi: 10.1002/14651858.CD001417.pub3.

Hemming K, Maguire MJ, Hutton JL, Marson AG. Vigabatrin for refractory partial epilepsy. Cochrane Database Syst Rev. 2013 Jan 31;1:CD007302. doi: 10.1002/14651858.CD007302.pub2.

Westall CA, Wright T, Cortese F, Kumarappah A, Snead OC 3rd, Buncic JR. Vigabatrin retinal toxicity in children with infantile spasms: An observational cohort study. Neurology. 2014 Dec 9;83(24):2262–8. doi: 10.1212/WNL.0000000000001069.

Al–Bachari S, Pulman J, Hutton JL, Marson AG. Gabapentin add–on for drug–resistant partial epilepsy. Cochrane Database Syst Rev. 2013 Jul 25;7:CD001415. doi: 10.1002/14651858.CD001415.pub2.

Lee SK. Old versus new: Why do we need new antiepileptic drugs? J Epilepsy Res. 2014 Dec 31;4(2):39–44.

National Center for Biotechnology Information. PubChem Compound Database; CID=34312. [citado 3.3.2015]. Disponible en: http://pubchem.ncbi.nlm.nih.gov/compound/34312

Kanemura H, Sano F, Sugita K, Aihara M. Effects of levetiracetam on seizure frequency and neuropsychological impairments in children with refractory epilepsy with secondary bilateral synchrony. Seizure. 2013 Jan;22(1):43–7. doi: 10.1016/j.seizure.2012.10.003.

Mbizvo GK, Dixon P, Hutton JL, Marson AG. Levetiracetam add–on for drug–resistant focal epilepsy: an updated Cochrane Review. Cochrane Database Syst Rev. 2012 Sep 12;9:CD001901. doi: 10.1002/14651858.CD001901.pub2.

National Center for Biotechnology Information. PubChem Compound Database; CID=5284583 [citado 3.3.2015]. Disponible en: http://pubchem.ncbi.nlm.nih.gov/compound/5284583

National Center for Biotechnology Information. PubChem Compound Database; CID=5486971 [citado 3.3.2015]. Disponible en: http://pubchem.ncbi.nlm.nih.gov/compound/5486971

Pulman J, Hemming K, Marson AG. Pregabalin add–on for drug–resistant partial epilepsy. Cochrane Database Syst Rev. 2014 Mar 12;3:CD005612. doi: 10.1002/14651858.CD005612.pub3.

Pulman J, Hutton JL, Marson AG. Tiagabine add–on for drug–resistant partial epilepsy. Cochrane Database Syst Rev. 2014 Feb 5;2:CD001908. doi: 10.1002/14651858.CD001908.pub3.

National Center for Biotechnology Information. PubChem Compound Database; CID=60648 [citado 3.3.2015]. Disponible en: http://pubchem.ncbi.nlm.nih.gov/compound/60648

National Center for Biotechnology Information. PubChem Compound Database; CID=3331. [citado 3.3.2015]. Disponible en: http://pubchem.ncbi.nlm.nih.gov/compound/3331

Enlaces refback

  • No hay ningún enlace refback.